Novo Nordisk Faces Mounting Challenges as Competition Intensifies

Novo Nordisk slashes drug prices in India and launches a US Wegovy subscription as Eli Lilly's new oral weight-loss drug intensifies competition, pressuring revenue and stock.

The Danish pharmaceutical giant Novo Nordisk finds itself navigating a complex landscape of patent expirations and aggressive new market entrants. The company is responding with significant pricing strategy shifts across key regions, aiming to defend its position in the lucrative GLP-1 therapy market.

Eli Lilly Accelerates Rivalry with New Approval

Competitive pressures escalated on April 2nd when the U.S. Food and Drug Administration granted accelerated approval to Eli Lilly's oral weight-loss drug, Foundayo (orforglipron). Slated for availability from April 6th, the treatment offers a practical advantage by requiring no food or fluid intake restrictions, unlike Novo Nordisk's oral Wegovy tablet, which mandates a 30-minute fasting period. Foundayo is priced at approximately $25 monthly for insured patients, with costs for self-payers ranging from $149 to $349. This move strengthens Eli Lilly's hold, which already commands over 60% of the U.S. obesity drug market.

Strategic Price Cuts and Subscription Models

In a dual-pronged approach to maintain market share, Novo Nordisk has implemented dramatic price reductions and new purchasing plans.

In India, where patent protection for injectable semaglutid expired, prices were slashed effective April 1, 2026. Wegovy now costs 48% less, while starter doses of Ozempic are priced 36% lower. This adjustment comes as over 40 local manufacturers, including Emcure Pharmaceuticals with its generic Poviztra priced near 3,999 rupees per month, have entered the market. With some local alternatives costing as little as 1,200 rupees, Novo Nordisk's price point of roughly 5,660 rupees for a monthly dose faces intense pressure.

Simultaneously, the company launched a U.S. subscription model for Wegovy on April 2nd. Patients committing to a 12-month plan pay a monthly fee of $249, applicable to both the injectable and the new tablet form. This represents an annual saving of about $1,200 compared to the previous list price. The initiative targets a significant market gap; currently, only 12% of eligible U.S. patients utilize GLP-1 therapies.

Financial Strain and Future Prospects

These competitive and pricing headwinds have heavily impacted Novo Nordisk's stock performance. Share values have declined by approximately 28% since the start of the year, trading near their 52-week low. For the full 2026 fiscal year, the company anticipates a revenue decrease of 5% to 13%. Further complicating the outlook, the firm is contending with more than 3,000 lawsuits alleging insufficient warnings about gastrointestinal side effects.

Investors are looking to the pipeline for a potential turnaround. The combination therapy CagriSema is viewed as a critical future catalyst, with an FDA decision expected in late 2026 or early 2027. In Phase 3 trials involving patients with Type 2 diabetes, the treatment demonstrated an average weight reduction of 14.2%, a result that could potentially reset market valuation for the company.